Every 8-K that TRULIEVE CANNABIS CORP (TCNNF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TCNNF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TCNNF filings page.
Trulieve Cannabis reported second-quarter 2026 revenue of $271 million, down 10% from a year earlier, with 94% from retail and medical-only revenue of $222 million. Gross profit was $162 million, a 60% margin.
GAAP net loss attributable to common shareholders was $406 million or $(2.10) per share, driven by a $403.3 million loss on deconsolidating its mixed medical and adult-use Harvest operations, which were restructured to enable listing on the NYSE. Adjusted net income was $20.4 million ($0.11 per share) and adjusted EBITDA $98 million, a 36% margin. Cash flow from operations reached $108.8 million year-to-date, free cash flow $74.4 million, and cash was $325.4 million against $289 million of debt at 9.6% interest.
Following federal rescheduling of state-licensed medical marijuana to Schedule III, Trulieve registered all medical facilities with the DEA, now operates 207 DEA-registered medical dispensaries and 3.5 million square feet of capacity, and retains a 90% economic interest in Harvest. The company also authorized a share repurchase program up to the lesser of $50 million or 8,495,038 subordinate voting shares and now expects at least $225 million of 2026 operating cash flow and up to $95 million of 2026 capital expenditures.
Trulieve Cannabis Corp. reported the results of a special meeting of shareholders held on August 5, 2026. Shareholders were asked to vote on a proposal regarding Delaware domestication of the company and on a separate adjournment proposal, both of which had been described in a definitive proxy statement filed on June 25, 2026.
The Delaware domestication proposal received 71,756,586 votes for, 383,078 votes against, and 50,472 abstentions. The adjournment proposal received 71,718,977 votes for, 358,779 votes against, and 112,380 abstentions.
Trulieve Cannabis Corp. reported a leadership change in its finance organization. As of June 30, 2026, the company eliminated the stand-alone role of Chief Accounting Officer and terminated Brett Walsh’s employment in that position without cause.
At the same time, Trulieve designated its Chief Financial Officer, Jan Reese, as principal accounting officer, consolidating the top finance and accounting responsibilities under one executive. The company noted that Reese will not receive any change or increase in compensation for assuming the additional accounting officer duties.
Trulieve Cannabis Corp. announced that President Jason Pernell has terminated his employment and his role as President effective June 11, 2026. The parties entered into a Separation Agreement and General Release that includes mutual releases of certain claims.
Mr. Pernell agreed not to sell, transfer, or otherwise monetize his Trulieve subordinate voting shares or other equity securities held in his name for one year from the Separation Agreement date. In return, and contingent on his compliance with the agreement, he remains eligible for his second quarter 2026 performance bonus and a prorated portion of his 2026 target performance bonus after 2026 earnings, receives a $15,000 severance payment, continued COBRA medical, dental, and vision premiums for up to 18 months or until he obtains similar coverage, and vesting of any issued and unvested annual equity awards as of the termination date.
Trulieve Cannabis Corp. reported results from its annual shareholder meeting, where investors approved all proposals on the agenda. Shareholders set the board size at seven directors, with 107,646,420 votes for and 1,235,766 against.
All seven director nominees were elected, each receiving over 48.9 million votes for, with substantial broker non-votes reflecting shares not voted on these items. Investors also backed, on a non-binding basis, the 2025 compensation of named executive officers, with 49,752,239 votes for and 1,997,073 against.
Shareholders ratified the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 107,441,983 votes for and 1,169,382 against. The filing also includes an Inline XBRL cover page data exhibit.
Trulieve Cannabis Corp. announced that its board authorized a share repurchase program allowing the company to buy back up to the lesser of $50 million in aggregate value or 8,495,038 subordinate voting shares, representing 5% of issued and outstanding subordinate voting shares as of June 8, 2026.
The program runs over a 12-month period and will expire on June 16, 2027. Trulieve is not obligated to repurchase any specific number of shares and may suspend, modify, or discontinue the program at its discretion, and any repurchased shares will be cancelled.
Trulieve Cannabis Corp. has completed a major restructuring of its U.S. operations by deconsolidating its former indirectly wholly owned subsidiary, Harvest Enterprises, LLC, into a separately controlled entity focused on mixed-use cannabis. Trulieve now holds only non-voting, non-participating units in Harvest, which are convertible into voting units only after a future “Stock Exchange Permissibility Date” when the NYSE permits consolidation of U.S. non-medical cannabis businesses. A new investor, Whitley Holding 05192026, LLC, acquired Class A voting units representing a 10% economic interest in Harvest for approximately $14.8 million and controls two of three board seats.
The transaction is designed to segregate Trulieve’s mixed-use cannabis business from its medical cannabis business so it can apply to list its subordinate voting shares on the New York Stock Exchange. Pro forma financials show Harvest removed from Trulieve’s historical results and the retained interest now accounted for under the equity method, with an estimated pre-tax loss on deconsolidation of about $688.7 million.
Trulieve Cannabis Corp. reported a profitable first quarter of 2026, generating revenue of $286.8 million and net income attributable to common shareholders of $2.4 million, after a loss a year earlier. Gross profit was $170.1 million, for a gross margin of about 59%.
The company produced adjusted EBITDA of $100.4 million, equal to a 35% margin, and free cash flow of $42.2 million from operating cash flow of $55.7 million and capital expenditures of $13.5 million. Cash rose to $352.9 million at March 31, 2026, while debt, including private placement notes, totaled $290 million at a 9.6% interest rate.
Management expects 2026 cash flow from operations of at least $250 million and capital expenditures of up to $85 million, and anticipates second-quarter 2026 revenue will increase by a low single-digit percentage versus the first quarter. The company highlighted U.S. federal rescheduling of medical marijuana to Schedule III, has applied for Drug Enforcement Agency registration for 206 state-licensed medical locations, and now operates 240 retail dispensaries and over four million square feet of cultivation and processing capacity.
Trulieve Cannabis Corp. reported that director Thad Beshears has notified the company he will not stand for reelection to the board at the annual meeting of shareholders scheduled for June 9, 2026. Beshears has served as a director since 2015, and his decision is stated to be not due to any disagreement with the company regarding its operations, policies, or practices.
Trulieve Cannabis Corp. is making a planned change in its top accounting role. The company has given Chief Accounting Officer Joy Malivuk notice that her employment will be terminated without cause, with her last day on May 28, 2026 after a 90‑day notice period. She will continue to receive her regular salary and benefits until that date and, afterward, will receive accrued salary and any earned but unpaid annual bonus for the prior fiscal year, plus severance, COBRA subsidies and accelerated vesting of equity awards as described in her employment agreement, subject to a release and other conditions.
Effective February 28, 2026, Trulieve has appointed Brett Walsh as Chief Accounting Officer and principal accounting officer. Under a new employment agreement effective March 5, 2026, he will receive a $245,000 annual base salary, be eligible for an annual bonus targeted at 20% of base salary for fiscal 2025 and 35% starting in fiscal 2026, and participate in equity and benefit plans consistent with senior management. The agreement also provides defined severance, COBRA coverage and equity vesting protections if he is terminated without cause or resigns for good reason, including enhanced benefits following a change of control.
Trulieve Cannabis Corp. reported largely stable 2025 results, pairing flat revenue with strong profitability metrics and cash generation. Full-year revenue was $1.2 billion, with 94% from retail, and GAAP gross profit reached $711 million for a 60% gross margin.
The company posted a 2025 GAAP net loss attributable to common shareholders of $116 million, while adjusted net loss narrowed to $27 million. Adjusted EBITDA hit a record $427 million, or 36% of revenue. Cash flow from operations was a record $273 million, and free cash flow was $229 million, supporting year-end cash of $256 million.
In the fourth quarter, revenue was $293 million, GAAP gross profit $175 million with a 60% margin, GAAP net loss $43 million, and adjusted EBITDA $105 million (36% margin). The company redeemed $368 million of 2026 notes, repaid a $15.8 million mortgage, and issued $140 million of 2030 notes, ending 2025 with $232 million of debt at a 9.4% rate.
Operationally, Trulieve sold a record 50.1 million branded units, grew its rewards program to 915,000 members, and finished with 233–234 dispensaries and over four million square feet of cultivation and processing capacity. It received conditional approval for a dispensing license in Texas and continues to challenge U.S. tax treatment under Section 280E, with an $668 million uncertain tax position liability; management notes that without 280E, both Q4 and full-year 2025 net income would have been positive.
Trulieve Cannabis Corp. reported executive compensation changes. Effective January 1, 2026, the Compensation Committee raised CEO Kim Rivers’ base salary from $850,000 to $900,000. Chief Production Officer Kyle Landrum’s base salary increased from $350,000 to $375,000, and Chief Technology Officer Nilyum Jhala’s salary also rose from $350,000 to $375,000.
For additional recognition of 2025 performance, Mr. Landrum received an extra 2025 bonus of $25,000, and Mr. Jhala received an extra 2025 bonus of $50,000 for services rendered.
Trulieve Cannabis Corp. has raised an additional U.S. $60 million through a private placement of 10.5% senior secured notes due December 17, 2030, bringing the total notes outstanding to U.S. $200 million. The new notes were priced at U.S. $1,000 plus U.S. $12.37 of accrued interest per U.S. $1,000 of principal.
The notes bear interest at 10.5% per year, paid semi-annually starting June 17, 2026, and are guaranteed by restricted subsidiaries and secured by a pledge of the shares of Trulieve US. They rank senior to Trulieve’s unsecured debt and are subject to covenants restricting additional debt, dividends, asset sales, investments, liens, affiliate transactions, and major corporate reorganizations.
Trulieve may redeem the notes at specified premiums beginning in 2027, and noteholders can require repurchase at 101% of principal upon a change of control. The company intends to use net proceeds for capital expenditures and other general corporate purposes.
Trulieve Cannabis Corp. issued $140 million of 10.5% senior secured notes maturing on December 17, 2030 in a private placement. The notes were priced at 100% of face value and pay interest semi-annually each June 17 and December 17, starting June 17, 2026.
The notes are guaranteed by restricted subsidiaries, currently including Trulieve, Inc., and are secured by a pledge of shares of Trulieve, Inc. Trulieve may redeem the notes at specified premiums starting December 17, 2027, and holders can require repurchase at 101% of principal plus accrued interest if there is a change of control.
The indenture includes covenants that limit additional indebtedness, liens, dividends, asset sales, certain investments, affiliate transactions and transfers of material permits. Trulieve plans to use the $140 million of gross proceeds for capital expenditures and other general corporate purposes.
Trulieve Cannabis Corp. announced it has received commitments for a private placement of $100 million in 10.5% Senior Secured Notes due on or about December 17, 2030. The Notes will be issued at 100% of face value, rank as senior secured obligations of the company, and carry a 10.5% annual interest rate, payable in equal semi-annual installments until maturity, redemption, or repurchase.
The Notes may be redeemed in whole or in part on or after the date that is two years following the issue date, at redemption prices to be set in a supplemental indenture. Trulieve intends to use the net proceeds from this Offering for capital expenditures and other general corporate purposes. The Notes are being sold in a private offering to qualified institutional buyers, accredited investors, and certain non‑U.S. persons under exemptions from U.S. securities registration requirements.
Trulieve Cannabis Corp. furnished an update on its business. The company announced its results for the three and nine months ended September 30, 2025 via a press release and provided an investor slide deck for conference use. Both materials are dated November 5, 2025 and were submitted as Exhibits 99.1 and 99.2. The company noted these materials are furnished, not filed, and therefore are not subject to Section 18 liability.
Trulieve Cannabis Corp. announced it will redeem all of its outstanding 8% Notes due October 6, 2026 for cash. The redemption covers US$368,000,000 principal as of November 4, 2025, at a price of 100% of principal plus accrued and unpaid interest up to, but excluding, the redemption date.
The redemption date is December 5, 2025. Payments and note surrender will occur through Odyssey Trust Company under the existing Indenture. The notes currently trade on the Canadian Securities Exchange as “TRUL.NT.U” and will be delisted in conjunction with the redemption.